Penumbra, Inc. (PEN)Healthcare | Medical Devices | Alameda, United States | NYSE
328.48 USD
-1.23
(-0.373%) ⇩
(April 21, 2026, 1:29 p.m.
EDT)
Short-term: ★★★★☆ | Long-term: ★★★☆☆ | Dividends: ★☆☆☆☆ |
Hot Take | April 19, 2026, 12:20 a.m. EDT
The imminent $14.5B Boston Scientific acquisition has shifted PEN from a growth play to a controlled-lottery ticket with a clear price target; while long-term valuation remains compressed by the $374+ mean target and high P/E, the short-term downside is effectively capped by the merger valuation, and the stock is structurally positioned for a squeeze toward the implied $400+ upside target once execution is confirmed. The rating reflects a 'long-term buy' vs conservative 'hold' by models, but the branded buyback via merger makes long-term الده ضرور. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.061313 |
| AutoARIMA | 0.061314 |
| MSTL | 0.061333 |
| AutoTheta | 0.069798 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 2.88 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 1.69 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 15.389 |
| Revenue per Share | 36.067 |
| Market Cap | 12,890,558,464 |
| Trailing P/E | 72.67 |
| Forward P/E | 51.50 |
| Beta | 0.84 |
| Profit Margins | 12.66% |
| Website | https://www.penumbrainc.com |
As of April 19, 2026, 12:20 a.m. EDT: Options flow indicates heavy long-term bullish positioning with massive Open Interest (OI) walls at $380, $400, and $450 for 2027 expirations, signaling a target price of $400+. Short expirations (May/July 2026) show balanced OTM Call/Put positioning near the $330-350 range, with elevated Vega (IV) suggesting uncertainty around the merger close. The significant disparity between ATM IV and Deep OTM OTM IVs implies the market is pricing in high volatility if the stock breaks out toward its long-term targets, while current speculation clusters heavily around the $380-$400 upside zone rather than deep downside protection.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.18934417 |
| Address1 | One Penumbra Place |
| All Time High | 362.41 |
| All Time Low | 35.315 |
| Ask | 328.14 |
| Ask Size | 80 |
| Audit Risk | 7 |
| Average Analyst Rating | 2.6 - Hold |
| Average Daily Volume10 Day | 416,940 |
| Average Daily Volume3 Month | 724,173 |
| Average Volume | 724,173 |
| Average Volume10Days | 416,940 |
| Beta | 0.839 |
| Bid | 328.01 |
| Bid Size | 40 |
| Board Risk | 5 |
| Book Value | 36.391 |
| City | Alameda |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 328.48 |
| Current Ratio | 6.644 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 330.065 |
| Day Low | 328.0 |
| Debt To Equity | 15.389 |
| Display Name | Penumbra |
| Earnings Call Timestamp End | 1,762,378,200 |
| Earnings Call Timestamp Start | 1,762,378,200 |
| Earnings Growth | 0.383 |
| Earnings Quarterly Growth | 0.406 |
| Earnings Timestamp | 1,772,049,600 |
| Earnings Timestamp End | 1,776,884,400 |
| Earnings Timestamp Start | 1,776,884,400 |
| Ebitda | 206,520,000 |
| Ebitda Margins | 0.14713 |
| Enterprise To Ebitda | 61.077 |
| Enterprise To Revenue | 8.986 |
| Enterprise Value | 12,613,709,824 |
| Eps Current Year | 5.03075 |
| Eps Forward | 6.37817 |
| Eps Trailing Twelve Months | 4.52 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 336.102 |
| Fifty Day Average Change | -7.6219788 |
| Fifty Day Average Change Percent | -0.022677576 |
| Fifty Two Week Change Percent | 18.934418 |
| Fifty Two Week High | 362.41 |
| Fifty Two Week High Change | -33.929993 |
| Fifty Two Week High Change Percent | -0.09362322 |
| Fifty Two Week Low | 221.26 |
| Fifty Two Week Low Change | 107.22002 |
| Fifty Two Week Low Change Percent | 0.48458835 |
| Fifty Two Week Range | 221.26 - 362.41 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,442,583,000,000 |
| Float Shares | 38,050,849 |
| Forward Eps | 6.37817 |
| Forward P E | 51.500668 |
| Free Cashflow | 92,686,248 |
| Full Exchange Name | NYSE |
| Full Time Employees | 4,700 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.67140996 |
| Gross Profits | 942,436,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.029979998 |
| Held Percent Institutions | 0.95324 |
| Implied Shares Outstanding | 39,243,053 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California. |
| Long Name | Penumbra, Inc. |
| Market | us_market |
| Market Cap | 12,890,558,464 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_28688621 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 177,687,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 12,938,827,004 |
| Number Of Analyst Opinions | 14 |
| Open | 329.75 |
| Operating Cashflow | 238,663,008 |
| Operating Margins | 0.1537 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.75 |
| Phone | 510 748 3200 |
| Previous Close | 329.71 |
| Price Eps Current Year | 65.29444 |
| Price Hint | 2 |
| Price To Book | 9.026408 |
| Price To Sales Trailing12 Months | 9.1835 |
| Profit Margins | 0.12659 |
| Quick Ratio | 4.013 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 2.64706 |
| Region | US |
| Regular Market Change | -1.2299805 |
| Regular Market Change Percent | -0.3730492 |
| Regular Market Day High | 330.065 |
| Regular Market Day Low | 328.0 |
| Regular Market Day Range | 328.0 - 330.065 |
| Regular Market Open | 329.75 |
| Regular Market Previous Close | 329.71 |
| Regular Market Price | 328.48 |
| Regular Market Time | 1,776,792,556 |
| Regular Market Volume | 532,710 |
| Return On Assets | 0.07041 |
| Return On Equity | 0.13781999 |
| Revenue Growth | 0.221 |
| Revenue Per Share | 36.067 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 39,243,053 |
| Shares Percent Shares Out | 0.0621 |
| Shares Short | 2,437,639 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 1,866,429 |
| Short Name | Penumbra, Inc. |
| Short Percent Of Float | 0.084 |
| Short Ratio | 3.75 |
| Source Interval | 15 |
| State | CA |
| Symbol | PEN |
| Target High Price | 374.0 |
| Target Low Price | 326.0 |
| Target Mean Price | 365.7857 |
| Target Median Price | 374.0 |
| Total Cash | 544,816,000 |
| Total Cash Per Share | 13.883 |
| Total Debt | 219,699,008 |
| Total Revenue | 1,403,665,024 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 4.52 |
| Trailing P E | 72.67257 |
| Trailing Peg Ratio | 0.7446 |
| Triggerable | 1 |
| Two Hundred Day Average | 291.36475 |
| Two Hundred Day Average Change | 37.115265 |
| Two Hundred Day Average Change Percent | 0.1273842 |
| Type Disp | Equity |
| Volume | 532,710 |
| Website | https://www.penumbrainc.com |
| Zip | 94,502 |